Unbiased Analysis of Today's Healthcare Issues
Samsung Bioepis has a Biosimilar Market Report for Q2 2024. Some key highlights: As of April 2024, the FDA has approved a total of 48 biosimilars across 15 unique biological molecules. Of the 48 approvals, 38 biosimilars have launched in the US market. In Q2 2024, 3 new biosimilars were approved in the US (Simlandi…
While robust data is preferred when parameterizing economic models, this information is not always available. For instance, it may be unclear the degree to which clinical trial results would translate to the real world. Or, clinical trial results may need to be extrapolated beyond the time period of the trial. Or, there may simply be…
I will be speaking on two panels at the upcoming ISPOR 2024 conference in Atlanta, GA. Myfirst panel “Economic Insights Into Nutrition: Unlocking the Value in Chronic Disease Management” on Tuesday, May 7, will discuss the opportunities and challenges of economic evaluation of nutrition interventions and compare economic analysis of nutrition interventions with analysis of…
Congratulations to Philipp Strack who has won the 2024 John Bates Clark Medal. The John Bates Clark Medal is awarded annually each April to that American economist under the age of forty who is judged to have made the most significant contribution to economic thought and knowledge. The American Economic Association webpage has a nice…
For patients with serious illnesses, timeline access to efficacious medications is paramount. The European Medicines Agency (EMA) was created in part to help expedite drug approvals and insure these products are save and effective. As stated in a paper by Grünwald and Stargardt (2024): The EMA [European Medicines Agency] was founded in 1995 primarily to…
That is the topic from a recent study by Hayes et al. (2024): Payments for some diagnostic scans undertaken in outpatient settings were unbundled from Diagnosis Related Group based payments in England in April 2013 to address under-provision. Unbundled scans attracted additional payments of between £45 and £748 directly following the reform. We examined the…
Generative AI for economists. Juvenile curfews on teenage birth rates. Cato on Biden Short‐Term Health Plans Rule. Parents’ education on children’s earnings. DTx for MDD.
A paper by Kogut (2024) has a nice overview of the organizations that develop pharmacy plan quality metrics. Pharmacy plan quality is vital since approximately 85% of the US population has prescription drug coverage through public (e.g., Medicare , Medicaid) or commercial (e.g., employer-provided) pharmacy plans. A helpful summary table is below. Quality measures are…
The Digital Therapeutics Alliance defines a digital therapeutic (DTx) as “evidence-based therapeutic interventions that are driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease.” One key question is what factors do US payers take into account when evaluating DTx and how does that differ from standard pharmaceuticals. A paper…
People won’t be surprised to learn that AI could improve the accuracy of diagnosis, expedite the rates of drug discovery, or even replace some (or many) activities typically done by doctors. However, can AI save the health care system money? That is the question asked by a recent article in The Economist titled “Can artificial…